16 Nov SIMPLAAFY Trial: Simpler Antithrombotic Regimens After WATCHMAN FLX Pro Left Atrial Appendage Closure
Health Notice: The aspirin-only and reduced-dose NOAC regimens discussed in this interview are investigational and are not part of the current device labeling. Antiplatelet and anticoagulant medications should only be prescribed, adjusted or stopped by your healthcare provider. Never change or stop blood-thinning medication on your own. This interview is for educational purposes and is not medical advice.
Editorial Notice: The interviewee is an employee of Boston Scientific, the manufacturer of the WATCHMAN FLX Pro device and the sponsor of the SIMPLAAFY trial. Products and providers are not warranted or endorsed by MedicalResearch.com or Eminent Domains Inc.

Dr. Brad Sutton, MD
MedicalResearch.com Interview with:
Dr. Brad Sutton, M.D.
Chief Medical Officer, AF Solutions
Boston Scientific
Antithrombotic Therapy After Left Atrial Appendage Occlusion: The SIMPLAAFY Randomized Clinical Trial
MedicalResearch.com: What is the background for this study? Would you briefly explain what the WATCHMAN FLX™ Pro Left Atrial Appendage Closure (LAAC) Device is indicated for?
Response: The SIMPLAAFY randomized controlled trial is evaluating whether simplified antithrombotic regimens following implantation of the WATCHMAN FLX™ Pro Left Atrial Appendage Closure (LAAC) Device can reduce bleeding risk while providing effective protection against device-related blood clots in patients with non-valvular atrial fibrillation (NVAF). While dual antiplatelet therapy (DAPT) helps prevent clotting as the heart tissue heals over the device, it also carries a risk of bleeding. The trial is comparing the safety and efficacy of on-label DAPT with two investigational monotherapy regimens: aspirin alone for the 12-month duration of the trial or reduced-dose non-vitamin K antagonist oral anticoagulant (NOAC) for the first three months followed by aspirin only. The six-month results were presented at the 2026 TCT Conference and simultaneously published in JAMA.
The WATCHMAN FLX Pro LAAC Device is designed to reduce stroke risk by closing the left atrial appendage, where stroke-causing blood clots can form in patients with NVAF. It represents an alternative approach to long-term oral anticoagulation for eligible patients who are at increased risk of stroke, are suitable for anticoagulation therapy and have an appropriate reason to seek a non-drug alternative. Patients with NVAF who have undergone prior cardiac ablation may also be eligible without needing a separate rationale for avoiding long-term anticoagulation. The device also features HEMOCOAT™ Technology, designed to promote faster, more controlled healing after implantation.
MedicalResearch.com: Please briefly explain DAPT vs NOAC therapies.
Response: DAPT, or dual antiplatelet therapy, uses two antiplatelet medications to help prevent blood clots by reducing platelet activity. NOACs, also called direct oral anticoagulants, are a different class of medication that works on the body’s blood-clotting system to reduce the formation of clots. Both approaches reduce thrombotic risk, but they do so through different mechanisms.
For patients implanted today, they are prescribed either two different antiplatelet medications (DAPT) or a full-dose NOAC.
MedicalResearch.com: What are the main findings?
Response: The SIMPLAAFY study found that at six months after the WATCHMAN FLX Pro LAAC device was implanted, both monotherapy post-implant drug regimen strategies met non-inferiority compared to the DAPT control arm, with less bleeding, less device-related thrombus (DRT) and similar rates of ischemic stroke.
The aspirin arm met the composite primary endpoint of death, stroke, systemic embolism or major bleeding, with aspirin demonstrating non-inferiority to DAPT (3.3% vs. 6.9%).
The reduced-dose NOAC arm also met the composite primary endpoint of death, stroke, systemic embolism or major bleeding, with reduced-dose NOAC demonstrating non-inferiority to DAPT (5.1% vs. 6.9%).
At six months, ischemic stroke rates in the trial were the same across the DAPT, reduced-dose NOAC and aspirin arms (0.7%).
In the trial, lower major and clinically relevant non-major bleeding rates were observed with both monotherapy strategies (7.3% with reduced-dose NOAC and 5.5% with aspirin) compared to DAPT (12.8%). Statistically significant reductions were observed for major bleeding with aspirin monotherapy and for clinically relevant non-major bleeding with both monotherapy strategies, each compared with DAPT. At 45 days, DRT rates were lowest with reduced-dose NOAC (0.9%) compared to aspirin (2.7%) and DAPT (3.4%).
MedicalResearch.com: What should readers take away from your report?
Response: The findings from the SIMPLAAFY trial provide meaningful prospective data to simplify antithrombotic management after uncomplicated LAAC procedures with the WATCHMAN FLX Pro device. This new evidence supports the potential for more personalized alternative regimens for patients and providers seeking to reduce post-implant bleeding risk, without compromising stroke protection or DRT risk. This further strengthens the body of clinical evidence supporting the WATCHMAN therapy, providing physicians with greater insight to inform treatment decisions.
Post-implant treatment should continue to be individualized according to the current label, procedural result, and the patient’s bleeding and thrombotic risks.
MedicalResearch.com: What recommendations do you have for future research as a result of this study?
Response: A full analysis of the trial data will be available after the 12-month follow-up is completed, and I hope that this study inspires further examination of the care experience for patients who have a variety of individual health characteristics, further enabling us to tailor the use of LAAC therapy for patients in the future.
MedicalResearch.com: Is there anything else you would like to add? Any disclosures?
Response: LAAC is an important stroke risk reduction option for appropriate patients with NVAF. Continued research through trials like SIMPLAAFY is essential to refining treatment approaches and optimizing patient care.
Disclosures: Dr. Brad Sutton is an employee of Boston Scientific.
Presented as a late-breaking clinical trial at Transcatheter Cardiovascular Therapeutics® (TCT®) 2026.
For a broader overview of the WATCHMAN FLX Pro device’s coating research, see this MedicalResearch.com interview on the novel coating on the WATCHMAN FLX Pro device.
The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Some links are sponsored. MedicalResearch.com and Eminent Domains Inc. do not warrant or endorse products or claims made by third party links. Always seek the advice of your physician or other qualified health provider and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.
Last Updated on November 16, 2026 by Marie Benz MD FAAD